Horizon says auto-immune disease candidate met another main goal in phase 2 trial
mohd izzuan/iStock via Getty Images

Horizon Therapeutics (NASDAQ:HZNP) announced Wednesday that dazodalibep, a candidate for autoimmune disease SjÃ¶grenâs syndrome, met the primary endpoint for the second population in a Phase 2 trial.
In September, the company said that dazodalibep also met the primary endpoint in the first study population with the moderate-to-high systemic disease.
The second study population comprised 109 patients with moderate-to-severe subjective symptoms, including dryness, pain, and fatigue.
In that group, dazodalibep-treated patients outperformed the placebo group at Day 169, achieving a 1.8-point reduction in ESSPRI scores, an indication of the symptomatic burden, compared to a 0.53-point decrease in the placebo group.
Additionally, the company said that there were statistically significant results for certain secondary quality-of-life measures such as fatigue. The study drug was well tolerated, with the commonest adverse events being COVID-19, nasopharyngitis, and anemia.
Horizon (HZNP) expects to share the results with the FDA to design a Phase 3 trial which is scheduled to begin in 2023, earlier than the previous timeline.
In December, Amgen (NASDAQ:AMGN) agreed to acquire Horizon Therapeutics (HZNP) for nearly $28B in cash.